News & Updates

Adding camrelizumab to platinum-based chemotherapy in the neoadjuvant treatment setting appears to improve the rate of pathologic complete response (pCR) in Asian patients with stage IIIA or IIIB non–small cell lung cancer (NSCLC), with manageable toxicity, according to data from the phase II TD-FOREKNOW study.

The Whipple procedure, a complex surgery also known as pancreaticoduodenectomy, is the treatment of choice for patients with pancreatic cancer located at the head of the pancreas.

For patients undergoing concurrent chemoradiotherapy (CCRT), treatment with either weekly or every-3-weeks fosaprepitant helps reduce nausea and vomiting caused by CCRT, with no difference in the effect, as reported in a study.

Treatment with the immune checkpoint inhibitor avelumab in the second-line setting confers survival and disease control benefits in patients with deficient mismatch repair and/or microsatellite instability (dMMR/MSI) metastatic colorectal cancer (mCRC) when compared with standard treatment, with a favourable safety profile, according to the results of the phase II SAMCO-PRODIGE 54 trial.

An expert-led public forum highlighted colorectal health awareness and early screening of people aged 45 and above, as key steps to reduce the burden of colorectal cancer (CRC) in Malaysia.

A competing risk model that incorporates lymph node parameters has demonstrated its utility and robustness in evaluating the results of the Cox proportional hazards model analysis among older patients with stage III serious ovarian cancer, reports a study.

Intensity-modulated radiation therapy (IMRT) helps reduce the risk of acute gastrointestinal toxicity, late genitourinary toxicity, and lower-extremity lymphedema (LEL) in patients with cervical cancer who underwent postoperative pelvic radiation therapy (PORT), a study has shown.

In the exploratory analyses of the phase III ASCEMBL trial, individuals with chronic myeloid leukaemia in chronic phase (CML-CP) who have failed ≥2 prior tyrosine kinase inhibitors (TKIs) continued to achieve deep responses with asciminib, the first BCR::ABL1 inhibitor to Specifically Target the ABL Myristoyl Pocket (STAMP).